Company Encyclopedia
View More
name
Biomea Fusion
BMEA.US
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It’s lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
1.907 T
BMEA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Biomea Fusion Inc. to Present at Jefferies London Healthcare Conference

    Biomea Fusion Inc. will present at the Jefferies London Healthcare Conference on November 17, 2025, participating in a fireside chat and one-on-one meetings. An audio webcast of the presentation will be available on the company's website. This announcement was originally published via GlobeNewswire on November 10, 2025.

    Reuters·
    US
    BMEA
    -1.80%
    Reuters·
    US
    BMEA
    -1.80%

    Biomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity

    Biomea Fusion Inc. has launched a Phase I trial for its oral GLP-1 agonist, BMF-650, aimed at obesity treatment. Preclinical data presented at ObesityWeek® 2025 showed significant weight loss and improved glycemic control in obese monkeys. The trial is currently enrolling healthy obese patients, with results expected in early 2026. Additionally, Biomea plans to evaluate its menin inhibitor, icovamenib, in type 2 diabetes patients by late 2025, with first dosing anticipated in early 2026.

    Reuters·
    US
    BMEA
    -1.80%
    Reuters·
    US
    BMEA
    -1.80%

    Oppenheimer Sticks to Their Buy Rating for Biomea Fusion (BMEA)

    According to TipRanks, Biegler is an analyst with an average return of -4.2% and a 38.97% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, CytomX Therapeutics, and Gilead Sciences. Currently, the analyst consensus on Biomea Fusion is a Strong Buy with an average price target of $7.00, representing a 455.56% upside. In a report released on October 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.

    Tip Ranks·
    US
    BMEA
    -1.80%
    Tip Ranks·
    US
    BMEA
    -1.80%

    Biomea Fusion Q3 net loss narrows

    Biomea Fusion reported a Q3 net loss of $16.4 million, down from $32.8 million last year. The company raised $68 million through public offerings, extending its cash runway into 2027. Positive Phase II data for Icovamenib supports further development, while the first patient has been dosed in the Phase I study for BMF-650. R&D expenses decreased significantly to $14.4 million. Analysts maintain a "buy" rating, with a median 12-month price target of $6.50, reflecting a potential 79.7% increase from the current price of $1.32.

    Reuters·
    US
    BMEA
    -1.80%
    Reuters·
    US
    BMEA
    -1.80%

    Biomea Fusion | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BMEA
    -1.80%
    LB filings·
    US
    BMEA
    -1.80%